RTP Mobile Logo
Oncology Grand Rounds Series: Part 1 — Non-Small Cell Lung Cancer
Released July 2017

Video proceedings from the first in a series of 7 integrated symposia held at the 2017 ONS Annual Congress. Featuring perspectives from Ms Kelly EH Goodwin, Dr Melissa Johnson, Dr Geoffrey R Oxnard and Ms Mollie Reed. (Video Program)

CE Disclosures and Faculty Information

    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of non-small cell lung cancer (NSCLC).

    NSCLC represents one of the most rapidly evolving fields in oncology. In just the past decade, a paradigm shift has occurred in the diagnosis and treatment of this disease from a “one-size-fits-all” approach to an often highly customized, biomarker-driven treatment algorithm. In addition, recent insights into how to harness the body’s own immune system have led to a new era in the management of this disease. As a result of the recent FDA approval of a number of new agents and the expansion of indications for others as well as the emergence of many pivotal data sets and novel agents potentially poised to further disrupt traditional management algorithms, it is essential that oncology clinicians have ample opportunity to maintain, refine and improve their knowledge.

    This is particularly true of oncology nurses, who play an integral role in the successful delivery of systemic anticancer therapy and the preservation of patient physical and psychosocial well-being. These video proceedings from the first part of a 7-part integrated CNE curriculum originally held at the 2017 ONS Annual Congress feature discussions with leading oncology investigators and their nursing counterparts regarding actual patient cases and recent clinical research findings affecting the optimal therapeutic and supportive care for each patient scenario.


    • Communicate the clinical relevance of tumor histology and commonly identified genetic abnormalities to patients with NSCLC.
    • Discuss the benefits and risks associated with systemic treatments used in the evidence-based treatment of metastatic NSCLC, including chemotherapeutic agents, targeted biologic therapies and novel immunotherapies.
    • Educate patients about potential side effects associated with existing and recently approved therapies, and provide preventive strategies to reduce or ameliorate these toxicities.
    • Assess research on the benefits of early palliative care for patients with metastatic NSCLC, and integrate this information, where appropriate, into patient consultations.
    • Recall the scientific rationale for ongoing investigation of novel agents and therapeutic approaches in NSCLC, and counsel appropriately selected patients about study participation.

    Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

    CNE credit is no longer available for this issue

    CNE credit is no longer available for this issue

    This is a video CNE program.
    CNE credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Kelly EH Goodwin, MSN, RN, ANP-BC
    Thoracic Cancer Center 
    Massachusetts General Hospital
    Boston, Massachusetts

    No relevant conflicts of interest to disclose.

    Melissa Johnson, MD
    Associate Director
    Lung Cancer Research
    Sarah Cannon Research Institute
    Nashville, Tennessee

    Consulting Agreements: Astellas Pharma Global Development Inc, Otsuka Pharmaceutical Co Ltd.

    Geoffrey R Oxnard, MD
    Lowe Center for Thoracic Oncology
    Dana-Farber Cancer Institute
    Assistant Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Advisory Committee: Ariad Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, Inivata, Takeda Oncology; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc.

    Mollie Reed, MSN, RN, ACNP-BC
    Nurse Practitioner
    Tennessee Oncology
    Sarah Cannon Research Institute
    Nashville, Tennessee

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Ipsen Biopharmaceuticals Inc, Taiho Oncology Inc; Speakers Bureau: Bristol-Myers Squibb Company, Genentech BioOncology, Merck, Novartis, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Taiho Oncology Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Biopharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Genentech BioOncology, Lilly, Merck, Novartis and Takeda Oncology.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: July 2017
    Expiration date: July 2018

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):